Analysis of results heterogeneity of NOACs vs warfarin.

Given are the main results (including all dosages or the dose with most pronounced efficacy result)* and grouping by regimen (BID or QD) are displayed. BID, twice-daily dosing; FEM, fixed-effects meta-analysis; NOACs, novel oral anticoagulants; QD, once-daily dosing.Note. Bold font marks nearly absence of heterogeneity, i.e., generation of a common estimate is justified.*Dose with most pronounced efficacy result: dabigatran 150 mg BID, apixaban 5/2.5 mg BID, rivaroxaban 20/15 mg QD, and edoxaban 60/30 mg QD.Analysis of results heterogeneity of NOACs vs warfarin.本数据集展示核心研究结果（涵盖全部给药剂量，或疗效最显著的给药剂量）*，并按给药方案（每日两次给药（twice-daily dosing, BID）或每日一次给药（once-daily dosing, QD））进行分组展示。其中，BID指代每日两次给药；固定效应meta分析（fixed-effects meta-analysis, FEM）；新型口服抗凝药（novel oral anticoagulants, NOACs）；QD指代每日一次给药。注：加粗字体表示异质性几乎不存在，即生成合并效应量的做法具备合理性。*疗效最显著的给药剂量具体为：达比加群酯（dabigatran）150mg BID、阿哌沙班（apixaban）5/2.5mg BID、利伐沙班（rivaroxaban）20/15mg QD以及依度沙班（edoxaban）60/30mg QD。新型口服抗凝药与华法林对比的结果异质性分析。